Page last updated: 2024-11-07

skullcapflavone ii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

skullcapflavone II: cytotoxic principle from Scutellariae radix; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

scullcapflavone II : A tetramethoxyflavone that is flavone substituted by methoxy groups at positions 6, 7, 8 and 6' and hydroxy groups at positons 5 and 2' respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID124211
CHEMBL ID465561
CHEBI ID9061
SCHEMBL ID3960981
MeSH IDM0136922

Synonyms (33)

Synonym
5,2'-dihydroxy-6,7,8,6'-tetramethoxyflavone
NCI60_040650
skullcapflavone ii
scullcapflavone ii
55084-08-7
nsc717846
nsc-717846
5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxychromen-4-one
chebi:9061 ,
CHEMBL465561
neobaicalein
LMPK12111423
bv62ean2vm ,
4h-1-benzopyran-4-one, 5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxy-
unii-bv62ean2vm
5,2'-dihydroxy-6,7,8,6'-tetramethoxy-flavone
SCHEMBL3960981
5-hydroxy-2-(2-hydroxy-6-methoxy-phenyl)-6,7,8-trimethoxy-chromen-4-one
5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxy-4h-1-benzopyran-4-one
AC-31924
DTXSID10203606
bdbm50478454
skullcapflavone ii, >=90% (lc/ms-uv)
Q27108257
2',5-dihydroxy-6,6',7,8-tetramethoxyflavone
5,6'-dihydroxy-6,7,8,2'-tetramethoxyflavone
HY-N6624
CS-0034412
FT-0776595
5-hydroxy-2-(2-hydroxy-6-methoxyphenyl)-6,7,8-trimethoxy-4h-chromen-4-one
MS-26043
E88602
AKOS040760119

Research Excerpts

Overview

Skullcapflavone II is a flavonoid derived from Scutellaria baicalensis. It is used in anti-inflammatory and anticancer therapy in Korea.

ExcerptReferenceRelevance
"Skullcapflavone II is a flavonoid derived from the root of "( Skullcapflavone II Inhibits Degradation of Type I Collagen by Suppressing MMP-1 Transcription in Human Skin Fibroblasts.
Lee, ST; Lee, YH; Seo, EK, 2019
)
3.4
"Skullcapflavone II is a flavonoid derived from Scutellaria baicalensis, a widely used herbal medicine in anti-inflammatory and anticancer therapy in Korea. "( Skullcapflavone II inhibits ovalbumin-induced airway inflammation in a mouse model of asthma.
Ahn, KS; Jang, HY; Kwon, OK; Lee, HK; Oh, SR; Park, MJ, 2012
)
3.26

Toxicity

ExcerptReferenceRelevance
" Accordingly, the inhibition of αSN fibrillation and elimination of toxic aggregates are the main therapeutic strategies."( Insights into the inhibitory mechanism of skullcapflavone II against α-synuclein aggregation and its mediated cytotoxicity.
Aliakbari, F; Bardania, H; Farhadpour, M; Hourfar, H; Mohammadi, M; Morshedi, D; Najarzadeh, Z; Parsafar, S; Seyedfatemi, SS, 2022
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-asthmatic drugA drug used to treat asthma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tetramethoxyflavoneAny methoxyflavone with four methoxy substituents.
dihydroxyflavoneAny hydroxyflavone in which two ring hydrogens are replaced by hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trypsin-1Homo sapiens (human)IC50 (µMol)110.00000.00351.532110.0000AID403947
Trypsin-2Homo sapiens (human)IC50 (µMol)110.00000.00351.58464.4000AID403947
Trypsin-3Homo sapiens (human)IC50 (µMol)110.00000.00351.58464.4000AID403947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID349305Binding affinity to GABAA receptor2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
QSAR modeling of the interaction of flavonoids with GABA(A) receptor.
AID403947Inhibition of trypsin-induced elevation in PAI1 production in HUVEC by ELISA1997Journal of natural products, Jun, Volume: 60, Issue:6
Effects of flavonoids isolated from scutellariae radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells.
AID1585505Inhibition of PCSK9 mRNA expression in human HepG2 cells at 20 uM after 24 hrs by qRT-PCR analysis relative to control2019European journal of medicinal chemistry, Jan-15, Volume: 162Small molecules as inhibitors of PCSK9: Current status and future challenges.
AID403948Inhibition of trypsin-induced reduction in tPA production in HUVEC by ELISA1997Journal of natural products, Jun, Volume: 60, Issue:6
Effects of flavonoids isolated from scutellariae radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.11)18.7374
1990's1 (5.56)18.2507
2000's2 (11.11)29.6817
2010's7 (38.89)24.3611
2020's6 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.18 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index19.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]